China’s health insurance and National Reimbursement Drug List (NRDL) are significant for innovative drug products to reach the market in hospitals. Reimbursement makes innovative drugs, usually at high prices, to be more affordable to patients.
For pharmaceutical companies, earning a place in the NRDL is an approach to widen market access for their drug products. But does NRDL listing a guarantee of sales growth? What is the role of NRDL, a list of drugs adjusted almost annually, in the market dynamics? This webinar organized by ChemLinked BaiPharm Portal is going to answer the questions.